LNA Santé SA operates and manages full-care facilities for the dependent elderly persons under the LNA Santé brand in France and Belgium.
Mediocre balance sheet with questionable track record.
Share Price & News
How has LNA Santé's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 2N3's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: 2N3 exceeded the German Healthcare industry which returned -23.4% over the past year.
Return vs Market: 2N3 matched the German Market which returned -17.7% over the past year.
Price Volatility Vs. Market
How volatile is LNA Santé's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is LNA Santé undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: 2N3 (€37.85) is trading above our estimate of fair value (€9.62)
Significantly Below Fair Value: 2N3 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 2N3 is good value based on its PE Ratio (16.8x) compared to the Healthcare industry average (27.4x).
PE vs Market: 2N3 is poor value based on its PE Ratio (16.8x) compared to the German market (16.4x).
Price to Earnings Growth Ratio
PEG Ratio: 2N3 is poor value based on its PEG Ratio (1.3x)
Price to Book Ratio
PB vs Industry: 2N3 is overvalued based on its PB Ratio (2x) compared to the DE Healthcare industry average (1.1x).
How is LNA Santé forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 2N3's forecast earnings growth (12.6% per year) is above the savings rate (-0.4%).
Earnings vs Market: 2N3's earnings (12.6% per year) are forecast to grow slower than the German market (14.3% per year).
High Growth Earnings: 2N3's earnings are forecast to grow, but not significantly.
Revenue vs Market: 2N3's revenue (7.7% per year) is forecast to grow faster than the German market (4.1% per year).
High Growth Revenue: 2N3's revenue (7.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 2N3's Return on Equity is forecast to be low in 3 years time (13.5%).
How has LNA Santé performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 2N3 has high quality earnings.
Growing Profit Margin: 2N3's current net profit margins (4%) are lower than last year (4.9%).
Past Earnings Growth Analysis
Earnings Trend: 2N3's earnings have grown significantly by 23.8% per year over the past 5 years.
Accelerating Growth: 2N3's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 2N3 had negative earnings growth (-13.4%) over the past year, making it difficult to compare to the Healthcare industry average (26%).
Return on Equity
High ROE: 2N3's Return on Equity (12.1%) is considered low.
How is LNA Santé's financial position?
Financial Position Analysis
Short Term Liabilities: 2N3's short term assets (€313.2M) do not cover its short term liabilities (€355.6M).
Long Term Liabilities: 2N3's short term assets (€313.2M) do not cover its long term liabilities (€647.2M).
Debt to Equity History and Analysis
Debt Level: 2N3's debt to equity ratio (154.6%) is considered high.
Reducing Debt: 2N3's debt to equity ratio has reduced from 249.4% to 154.6% over the past 5 years.
Debt Coverage: 2N3's debt is well covered by operating cash flow (33.2%).
Interest Coverage: 2N3's interest payments on its debt are well covered by EBIT (4.3x coverage).
Inventory Level: 2N3 has a high level of physical assets or inventory.
Debt Coverage by Assets: 2N3's debt is covered by short term assets (assets are 1.1x debt).
What is LNA Santé's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 2N3's dividend (1.01%) isn’t notable compared to the bottom 25% of dividend payers in the German market (1.7%).
High Dividend: 2N3's dividend (1.01%) is low compared to the top 25% of dividend payers in the German market (4.97%).
Stability and Growth of Payments
Stable Dividend: Whilst dividend payments have been stable, 2N3 has been paying a dividend for less than 10 years.
Growing Dividend: 2N3's dividend payments have increased, but the company has only paid a dividend for 4 years.
Current Payout to Shareholders
Dividend Coverage: With its low payout ratio (17%), 2N3's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: 2N3's dividends in 3 years are forecast to be well covered by earnings (16.8% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Jean Siret (67yo)
Mr. Jean paul siret has been the Chairman and Chief Executive Officer of le noble-age., since july 30, 1992. He also serves as Founder of LNA Santé SA. Mr. Siret served as the chief executive officer of sa ...
CEO Compensation Analysis
Compensation vs Market: Jean's total compensation ($USD359.24K) is below average for companies of similar size in the German market ($USD1.03M).
Compensation vs Earnings: Jean's compensation has been consistent with company performance over the past year.
|Deputy Director General of Finance & Director||10.75yrs||€278.00k||0.031% €113.5k|
|Deputy Director General of Operations & Director||13.92yrs||€278.00k||0.34% €1.3m|
|Independent Director||8.75yrs||€14.00k||no data|
|Director||7.75yrs||no data||no data|
|Independent Director||5.75yrs||€13.00k||no data|
|Independent Director||3.17yrs||€14.00k||no data|
|Independent Director||2.75yrs||€13.00k||no data|
Experienced Board: 2N3's board of directors are considered experienced (8.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
LNA Santé SA's company bio, employee growth, exchange listings and data sources
- Name: LNA Santé SA
- Ticker: 2N3
- Exchange: DB
- Founded: 1990
- Industry: Health Care Facilities
- Sector: Healthcare
- Market Cap: €362.350m
- Shares outstanding: 9.65m
- Website: https://www.lna-sante.com
Number of Employees
- LNA Santé SA
- 7 Boulevard Auguste Priou
- PO Box 32336
- Pays de la Loire
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|LNA||ENXTPA (Euronext Paris)||Yes||Common Shares||FR||EUR||Jun 2006|
|0OR2||LSE (London Stock Exchange)||Yes||Common Shares||GB||EUR||Jun 2006|
|LNAP||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Common Shares||GB||EUR||Jun 2006|
|2N3||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Jun 2006|
LNA Santé SA operates and manages full-care facilities for the dependent elderly persons under the LNA Santé brand in France and Belgium. The company operates nursing homes, follow-up care and rehabilitation facilities, home hospitalization structures, health centers, and psychiatric clinics. It serves patients with complex, acute, or chronic pathologies comprising neurological, respiratory, cardiovascular, psychiatric, etc. The company operates 11 clinics; 1 psychiatric clinic; and 7 home care facilities. LNA Santé SA was founded in 1990 and is based in Vertou, France.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/03/30 00:15|
|End of Day Share Price||2020/03/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.